Stay updated on Pembrolizumab Combo in ES-SCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in ES-SCLC Clinical Trial page.

Latest updates to the Pembrolizumab Combo in ES-SCLC Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedThe two screenshots show no substantive changes to the study details, eligibility criteria, endpoints, or locations; any differences appear to be minor formatting or wording adjustments that do not affect the page's purpose. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check40 days agoChange DetectedCore content updated with an operating-status notice and a new version (v3.2.0); a specific resource (Small cell lung carcinoma) was removed (v3.1.0).SummaryDifference2%

- Check47 days agoChange DetectedThe page update adds the new version tag v3.1.0 and removes the old v3.0.2 tag, signaling a software version upgrade.SummaryDifference0.0%

- Check61 days agoChange DetectedRevision updated from v3.0.1 to v3.0.2. The 'Back to Top' element was removed (a minor UI change).SummaryDifference0.1%

- Check68 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes in core content, pricing, or availability.SummaryDifference0.1%

- Check75 days agoChange DetectedThe web page has undergone significant updates, including the addition of detailed drug information for various medications and the inclusion of numerous specific locations across multiple countries. Notably, the facility name and location have been added, enhancing the core content of the page.SummaryDifference12%

Stay in the know with updates to Pembrolizumab Combo in ES-SCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in ES-SCLC Clinical Trial page.